Prime-boost vectored malaria vaccines: Progress and prospects

Hill, Adrian V. S.; Reyes-Sandoval, Arturo; O’Hara, Geraldine; Ewer, Katie; Lawrie, Alison M.; Goodman, Anna; Nicosia, Alfredo; Folgori, Antonella; Colloca, Stefano; Cortese, Riccardo; Gilbert, Sarah C.; Draper, Simon J.

doi:10.4161/hv.6.1.10116

Cited by 189 publications

(165 citation statements)

References 47 publications

Supporting

Mentioning

163

Contrasting

Order By: Relevance

“…Adenovirus-MVA prime-boost regimens are currently one of the leading strategies to induce potent immune responses against vaccine antigens (21,22). BALB/c mice (n=18 (6 per group)) received a priming vaccination of either ChAdOx1-NP+M1, ChAdOx1-H7, or both, administered separately into opposite limbs, as described.…”

Section: Prime-boost Regimen Incorporating Simian Adenoviral Vectors mentioning

confidence: 99%

Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge

Chinnakannan

Mullarkey

Ulaszewska

et al. 2017

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

Abstract:Seasonal influenza viruses (IAV) are a common cause of acute respiratory illness worldwide and generate a significant socio-economic burden. IAV rapidly mutate, necessitating annual vaccine reformulation as traditional vaccines do not typically induce broad-spectrum immunity. In addition to seasonal infections, emerging pandemic influenza viruses present a continued threat to global public health. Pandemic influenza viruses have consistently higher attack rates and are typically associated with greater mortality as compared to seasonal strains. Ongoing strategies to improve vaccine efficacy typically focus on providing broad-spectrum immunity, and while both B and T cells can mediate heterosubtypic responses, typical vaccine development will augment either humoral or cellular immunity. However, multipronged approaches, targeting several antigens, may limit the generation of viral escape mutants. There are few vaccine platforms that can deliver multiple antigens and generate robust cellular and humoral immunity. In this work, we describe a novel vaccination strategy, tested pre-clinically in mice, for the delivery of novel bivalent viral-vectored vaccines. Here, we show this strategy elicits potent T cell responses toward highly conserved internal antigens, whilst simultaneously inducing high levels of antibodies towards hemagglutinin (HA). Importantly, these humoral responses generate longlived plasma cells and generate antibodies capable of neutralising variant HA-expressing pseudotyped lentiviruses. Significantly, these novel viral-vectored vaccines induce strong immune responses capable of conferring protection in a stringent influenza A virus challenge.Thus, this vaccination regimen induces lasting efficacy toward influenza. Importantly, the simultaneous delivery of dual antigens may alleviate the selective pressure thought to potentiate antigenic diversity in avian influenza viruses.

show abstract

Section: Prime-boost Regimen Incorporating Simian Adenoviral Vectors mentioning

confidence: 99%

Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge

Chinnakannan

Mullarkey

Ulaszewska

et al. 2017

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Virus-based vaccines may be particularly suited to induce CD8 + T cells. Experience in other fields 63 and the results of several studies that explored experimental anti-Leishmania vaccines 57,59,64,65 suggest that prime boost combinations with heterologous vaccine formulations offer synergies that may become very important. We choose to refine the approach of using recombinant, live salmonella (see Fig.…”

Section: Vaccine Formulationsmentioning

confidence: 99%

Vaccines for Leishmaniasis: From proteome to vaccine candidates

Schroeder¹,

Aebischer²

2011

Human Vaccines

View full text Add to dashboard Cite

“…All subsequent antibody incubations were performed using the same conditions. The cells were washed two times and stained with 25 …”

Section: Polychromatic Flow Cytometry Assaymentioning

confidence: 99%

“…Each vector and vector-immunogen combination is likely to have unique biological and immunological properties. While some vectors are better for priming, others excel in boosting [23][24][25] and although some general rules are emerging, combining vaccines into more complex heterologous regimens remains largely empirical.Attenuated Mycobacterium bovis bacillus Calmette-Guérin (BCG) is administered to a majority of African infants at birth as a vaccine against tuberculosis. Because of its many attractive features, BCG is explored as a vector for subunit vaccines against other illnesses particularly for developing countries [26].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Optimizing HIV‐1‐specific CD8⁺ T‐cell induction by recombinant BCG in prime‐boost regimens with heterologous viral vectors

et al. 2011

View full text Add to dashboard Cite

The desire to induce HIV-1-specific responses soon after birth to prevent breast milk transmission of HIV-1 led us to propose a vaccine regimen which primes HIV-1-specific T cells using a recombinant Mycobacterium bovis bacillus Calmette-Gué rin (rBCG) vaccine. Because attenuated live bacterial vaccines are typically not sufficiently immunogenic as stand-alone vaccines, rBCG-primed T cells will likely require boost immunization(s). Here, we compared modified Danish (AERAS-401) and Pasteur lysine auxotroph (222) strains of BCG expressing the immunogen HIVA for their potency to prime HIV-1-specific responses in adult BALB/c mice and examined four heterologous boosting HIVA vaccines for their immunogenic synergy. We found that both BCG.HIVA 401 and BCG.HIVA 222 primed HIV-1-specific CD8 1 T-cell-mediated responses. The strongest boosts were delivered by human adenovirus-vectored HAdV5.HIVA and sheep atadenovirus-vectored OAdV7.HIVA vaccines, followed by poxvirus MVA.HIVA; the weakest was plasmid pTH.HIVA DNA. The prime-boost regimens induced T cells capable of efficient in vivo killing of sensitized target cells. We also observed that the BCG.HIVA 401 and BCG.HIVA 222 vaccines have broadly similar immunologic properties, but display a number of differences mainly detected through distinct profiles of soluble intercellular signaling molecules produced by immune splenocytes in response to both HIV-1-and BCG-specific stimuli. These results encourage further development of the rBCG prime-boost regimen.Key words: BCG . HIV . Mother-to-child transmission . Prime-boost . T cells . Vaccines Supporting Information available online IntroductionIt is 30 years since the first cases of AIDS were described, yet HIV-1 infection continues to take its toll particularly in resourcepoor areas such as many parts of sub-Saharan Africa [1]. About half of the infected adults are women of childbearing age, who will expose their babies to HIV-1 during pregnancy, delivery and breastfeeding [2]. Although antiretroviral treatment substantially decreases mother-to-child transmission (MTCT) of HIV-1 [3], it is not ideal due to the cost, requirement for daily compliance, side effects and possible development of drug resistance. Because breast milk provides essential nutrients and protection against 3542other diseases in the early days of life [4,5], formula as an HIV-1-free alternative is recommended only if it is acceptable, feasible, affordable, sustainable and safe (AFASS) and thus it is not an option for many HIV-1-positive mothers in Africa. The best hope for protecting newborns and infants in the 'South' (and in the 'North') against acquiring HIV-1 from their infected mothers while breastfeeding remains the development of safe, effective and accessible adult and pediatric vaccines [6]. For babies born to HIV-1-positive mothers, induction of anti-HIV-1 immunity as soon as possible after birth is highly desirable and may provide a basis for lifetime protection, which can be maintained by boosts later in life.A successful HIV-1 vaccine may ...

show abstract

Prime-boost vectored malaria vaccines: Progress and prospects

Cited by 189 publications

References 47 publications

Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge

Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge

Vaccines for Leishmaniasis: From proteome to vaccine candidates

Optimizing HIV‐1‐specific CD8⁺ T‐cell induction by recombinant BCG in prime‐boost regimens with heterologous viral vectors

Contact Info

Product

Resources

About

Prime-boost vectored malaria vaccines: Progress and prospects

Cited by 189 publications

References 47 publications

Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge

Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge

Vaccines for Leishmaniasis: From proteome to vaccine candidates

Optimizing HIV‐1‐specific CD8+ T‐cell induction by recombinant BCG in prime‐boost regimens with heterologous viral vectors

Contact Info

Product

Resources

About

Optimizing HIV‐1‐specific CD8⁺ T‐cell induction by recombinant BCG in prime‐boost regimens with heterologous viral vectors